X

Trial Profile

Phase II Trial Evaluating Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms IMANOL; SOGUG-IMANOL

Most Recent Events

18 Feb 2023 Results (n=134; since Feb-2018 to Nov-2020) assessing efficacy and safety of olaparib maintenance in patients with metastatic castration resistant prostate cancer, presented at the 2023 Genitourinary Cancers Symposium.
02 Nov 2022 Status changed from active, no longer recruiting to completed.
08 Feb 2022 Planned End Date changed from 1 Feb 2022 to 1 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com